Population pharmacokinetic and exposure–efficacy analysis of ixekizumab in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS)

Aims Ixekizumab is a high‐affinity monoclonal antibody that selectively targets interleukin‐17A used in the treatment of adult and paediatric patients with moderate‐to‐severe psoriasis. This analysis evaluated the pharmacokinetics (PK) of ixekizumab and the exposure–efficacy relationship in paediatr...

Full description

Saved in:
Bibliographic Details
Published in:British journal of clinical pharmacology 2022-03, Vol.88 (3), p.1074-1086
Main Authors: Jackson, Kimberley, Chua, Laiyi, Velez de Mendizabal, Nieves, Pitou, Celine, Rodriguez Capriles, Claudia, Paller, Amy S., Lansang, Perla, Seyger, Marieke M. B., Papp, Kim
Format: Article
Language:English
Subjects:
Adult
Antibodies, Monoclonal, Humanized
Child
Double-Blind Method
Humans
ixekizumab
Original
paediatric
pharmacokinetics
pharmacokinetics‐pharmacodynamics
population pharmacokinetics
psoriasis
Psoriasis - drug therapy
Severity of Illness Index
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims Ixekizumab is a high‐affinity monoclonal antibody that selectively targets interleukin‐17A used in the treatment of adult and paediatric patients with moderate‐to‐severe psoriasis. This analysis evaluated the pharmacokinetics (PK) of ixekizumab and the exposure–efficacy relationship in paediatric patients aged 6 to
ISSN:0306-5251
1365-2125
DOI:10.1111/bcp.15034